

37. Radin NS. Chemical models and chemotherapy in the sphingolipidoses. In; Volk BW, Schneck L, editors. *Current Trends in Sphingolipidoses and Allied Disorders*. New York: Plenum Press; 1976. p. 453.
38. Lachmann RH. Miglustat. *Oxford GlycoSciences/Acteliun. Curr Opin Investig Drugs*. 2003; 4: 472.
39. Butters TD, Mellor HR, Narita K, Dwek RA, Plat FM. Small -molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. *Philos Trans R Soc Lond B Biol Sci*. 2003 May 29; 358 (1433): 927-45.
40. Moyses C. Substrate reduction therapy: Clinical evaluation in type I Gaucher disease. *Philos Trans R Soc Lond B Biol Sci*. 2003; 358:955.
41. Zimran A, Elstein D. Gaucher disease and the clinical experience with substrate reduction therapy. *Philos Trans R Soc Lond B Biol Sci*. 2003; 358: 961.
42. McCormack PL, Goa KL. Miglustat. *Drugs* 2003, 63: 2427.
43. Amstutz HC. The hip in Gaucher's disease. *Clin Orthop*. 1973, 90: 83.
44. Davies FWT. Gaucher's disease in bone. *J Bone Joint Surg Br*. 1952; 34B: 454.
45. Schein AJ, Arkin AM. The classic: Hip joint involvement in Gaucher's disease. *Clin Orthop*. 1973; 90: 4.
46. Moore M Jr, Coley BL. Bone lesions in Gaucher's disease. *J Tenn Med Assoc*. 1947; 40: 101.
47. Takiyama N, Mohny T, Swaney W, Bahnson AB, Rice E, Beeler M, et al. Comparison of methods for retroviral mediated transfer of glucocerebrosidase gene to CD34 + hematopoietic progenitor cells. *Eur J Haematol*. 1998 Jul; 61(1): 1-6.
48. Schuening F, Longo WL, Atkinson ME, Zaboikin M, Kiem HP, Sanders J, et al. Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease *Hum Gene Ther*. 1997 Nov; 20; 8(17) 2143-60.
49. Dunbar C, Kohn D. Retroviral mediated transfer of the cDNA for human glucocerebrosidase into hemopoietic stem cells of patients with Gaucher disease. A phase I study. *Hum Gene Ther*. 1996 Jan 20; 7(2): 231-53.
50. Nolte JA, Sender LS, Barranger JA, Kohn DB. Expression of human glucocerebrosidase in murine long-term bone marrow cultures after retroviral vector-mediated transfer. *Blood* 1990 Feb 1; 75(3): 787-97.
51. Sorge J, Kuhl W, West C, Beuther E. Gaucher disease: Retroviral-mediated correction of the enzymatic defect in cultured cells. *Cold Spring Harb Symp Quant Biol*. 1986; 51 Pt 2: 1041-6.
52. Kohl DB, Gene therapy for genetic haematological disorders and immunodeficiencies. *J Intern Med*. 2001; 249:379.
53. Fan JQ. A contradictory treatment for lysosomal storage disorders: Inhibitors enhance mutant enzyme activity. *Trends Pharmacol Sci*. 2003; 24: 355.
54. Silverstein MN, Kelly PJ. Osteoarticular manifestations of Gaucher's disease. *Am J Med Sci*. 1967; 253: 569.
55. Ashkenazi A, Zaizov R, Matoth Y: Effect of splenectomy on destructive bone changes in children with chronic (type I) Gaucher disease. *Eur J Pediatr*. 1986; 145: 138.
56. Shiloni E, Bitran D, Rachmilewiz E, Durst AL: The role of splenectomy in Gaucher's disease. *Arch Surg*. 1983 Aug; 118(8): 929-32.
57. Lee RE. The pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowshki GA editors. *Gaucher Diseases: A Century of Delineation and Research*. New York: Alan R. Liss; 1982: p. 177.